The present disclosure provides a transdermal delivery systems for delivering donepezil free base to patients suffering from central nervous system disorders including dementia and Alzheimer's. The transdermal delivery systems can have a separating layer having at least one surface with a surface energy of at least 40 Dynes, sodium bicarbonate particles in the drug matrix layer where the sodium bicarbonate particles have a D90 particle size of from 0.1 μm to 1000 μm, or a combination thereof.

The present disclosure provides a transdermal delivery systems for delivering donepezil free base to patients suffering from central nervous system disorders including dementia and Alzheimer's. The transdermal delivery systems can have a separating layer having at least one surface with a surface energy of at least 40 Dynes, sodium bicarbonate particles in the drug matrix layer where the sodium bicarbonate particles have a D90 particle size of from 0.1 μm to 1000 μm, or a combination thereof.

Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.

Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.

The present disclosure provides novel methods of maturing an AVF at the time of fistula creation comprising administering to an AVF a composition comprising at least one active agent chosen from a Compound of Formula (I) and pharmaceutically acceptable salts thereof and illuminating the at least one active agent on said AVF with visible light, such as, for example, 450 nm light.

The present disclosure provides novel methods of maturing an AVF at the time of fistula creation comprising administering to an AVF a composition comprising at least one active agent chosen from a Compound of Formula (I) and pharmaceutically acceptable salts thereof and illuminating the at least one active agent on said AVF with visible light, such as, for example, 450 nm light.

The present application relates to small molecule inhibitors of human deubiquitinases for use in the prevention or treatment of a coronaviral infection. It relates in particular to small molecule inhibitors of USP7 and USP47. Pharmaceutical compositions, respective advantageous formulation techniques and a method of treatment are disclosed.

The disclosure relates to compositions comprising PU.1 inhibitors as well as methods of making and using the same. In some embodiments, methods of screening compounds for PU.1 inhibition are disclosed. In some embodiments, methods of screening a plurality of compounds for PU.1 inhibition are disclosed. In some embodiments, lambda-beta binding (LBB) motifs are used to screen compounds for PU.1 inhibition. In some embodiments, methods of treating neurodegenerative disorders are disclosed. In some embodiments pharmaceutical compounds are provided. In some embodiments, methods of treating Alzheimer's disease, inflammation, or excessive myelin uptake with PU.1 inhibitors are disclosed.

A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.